Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:37:51 EDT Tue 28 Mar 2023
Enter Symbol
or Name
USA
CA



News for U:ALBO from 2022-03-29 to 2023-03-28 - 39 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-02-14 08:30U:ALBONews ReleaseFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay ‚ ® in Alagille Syndrome
2022-12-20 16:30U:ALBONews ReleaseAlbireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-12-19 08:30U:ALBONews ReleaseAlbireo Submits Bylvay ‚ ® Alagille Syndrome Regulatory Filings to FDA and EMA
2022-12-06 16:30U:ALBONews ReleaseAlbireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-12-06 08:30U:ALBONews ReleaseAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & ‚  Craig Hopkinson, M.D., to Board of Directors
2022-11-09 08:30U:ALBONews ReleaseAlbireo to Participate in Jefferies London Healthcare Conference
2022-11-08 16:01U:ALBONews ReleaseAlbireo Reports Q3 2022 Financial Results and Business Update
2022-11-07 08:30U:ALBONews ReleaseBylvay(TM) (odevixibat) Data Presented at AASLD The Liver Meeting(TM) 2022, Demonstrating Native Liver Survival in Children Across PFIC Types
2022-11-03 08:30U:ALBONews ReleaseAlbireo Announces 2022 SPARK Grant Winners
2022-11-02 08:30U:ALBONews ReleaseAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
2022-11-01 08:30U:ALBONews ReleaseAlbireo to Present Late Breaking Bylvay(TM) (odevixibat) Data at AASLD 2022
2022-10-31 08:30U:ALBONews ReleaseAlbireo to Report Q3 2022 Financial Results on November 8, 2022
2022-10-13 08:30U:ALBONews ReleaseAlbireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay(TM) Treatment at NASPGHAN
2022-10-12 08:30U:ALBONews ReleaseAlbireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
2022-10-11 07:00U:ALBONews ReleaseAlbireo Reports Positive Topline Data from Phase 3 Trial of Bylvay(TM) (odevixibat) in Alagille Syndrome
2022-10-05 08:30U:ALBONews ReleaseAlbireo to Showcase New Data at AASLD The Liver Meeting(TM) 2022
2022-09-27 16:30U:ALBONews ReleaseAlbireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-09-22 08:30U:ALBONews ReleaseAlbireo Announces $115 Million Royalty Monetization Agreement with Sagard
2022-09-20 08:00U:ALBONews ReleaseAlbireo to Participate in Guggenheim Nantucket Therapeutics Conference
2022-09-06 08:00U:ALBONews ReleaseItalian Medicines Agency Approves Reimbursed Access to Bylvay(TM) (odevixibat) For Patients with All PFIC Types
2022-09-01 08:00U:ALBONews ReleaseAlbireo to Participate in Upcoming Investor Conferences
2022-08-22 17:13U:ALBONews ReleaseAlbireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-08-15 16:05U:ALBONews ReleaseAlbireo Reports Q2 2022 Financial Results and Business Update
2022-08-10 08:30U:ALBONews ReleaseAlbireo Appoints New Members to Board of Directors
2022-08-03 08:30U:ALBONews ReleaseAlbireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
2022-08-01 08:30U:ALBONews ReleaseAlbireo to Report Q2 2022 Financial Results on August 15, 2022
2022-07-26 16:30U:ALBONews ReleaseAlbireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-07-06 08:30U:ALBONews ReleaseThe Lancet Gastroenterology & Hepatology Publishes Data from Albireo's Landmark PEDFIC 1 Study of Bylvay(TM) (odevixibat) Treatment in PFIC
2022-06-30 08:00U:ALBONews ReleaseAlbireo to Present at the William Blair Biotech Focus Conference 2022
2022-06-24 08:30U:ALBONews ReleaseAlbireo Presents New Bylvay(TM) (odevixibat) Data at Annual ESPGHAN Congress
2022-06-23 08:30U:ALBONews ReleaseAlbireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
2022-06-08 08:30U:ALBONews ReleaseAlbireo to Present New Data at the EASL International Liver Congress(TM) 2022
2022-06-07 08:30U:ALBONews ReleaseAlbireo to Present New Data at the 54th Annual Meeting of ESPGHAN
2022-06-02 16:30U:ALBONews ReleaseAlbireo to Participate at Upcoming Investor Conferences
2022-05-23 08:30U:ALBONews ReleaseAlbireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
2022-05-19 16:30U:ALBONews ReleaseAlbireo to Participate in the H.C. Wainwright Global Investment Conference 2022
2022-05-16 16:01U:ALBONews ReleaseAlbireo Reports Q1 2022 Financial Results and Business Update
2022-05-09 08:30U:ALBONews ReleaseAlbireo to Report Q1 2022 Financial Results on May 16
2022-03-29 08:30U:ALBONews ReleaseAlbireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome